Medical/Pharmaceuticals

SpaceGut's Precision AI System for Gut Testing Achieves Up to 87% Improvement in Irritable Bowel Syndrome Management

KUALA LUMPUR, Malaysia, Sept. 8, 2025 /PRNewswire/ -- SpaceGut , Malaysia's first AI-powered at-home Gut Microbiome Test Kit

2025-09-08 20:37 1809

Medit Expands Orthodontic Suite with Launch of Medit Aligners: Premium Comfort, Precision, and Speed for Modern Orthodontics

NEWPORT BEACH, Calif., Sept. 8, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, today announced the launch ofMedit Aligners, a premium digital clear aligner solution designed to deliver faster turnaround times and more predictable outcomes for orthodontic patients. ...

2025-09-08 20:30 1397

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year

SHANGHAI, Sept. 8, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has received the Gold Medal by EcoVadis sustainability rating for the s...

2025-09-08 20:00 1334

BrainCo Helps Amputee Showcase Technology at WAIC 2025

BOSTON, Sept. 8, 2025 /PRNewswire/ -- At the 2025 World Artificial Intelligence Conference (WAIC) inAugust 2025, Gu demonstrated the BrainCo Intelligent Bionic Hand. He played the piano with precision and even explained to attendees how brain-computer interface (BCI) technology enables amputees t...

2025-09-08 19:29 1104

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 /PRNewswire/ -- Echosens , the leader in non-invasive liver diagnostics, is...

2025-09-08 18:00 1133

Remplir™ Study Delivers Compelling 81% Success Rate

Data to support US sales roll out and EU + UK regulatory submissions  * Interim results from a new Remplir™ study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. * Real World Evidence (RWE) patient data collected in the study confirms Ortho...

2025-09-08 17:32 1472

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

* Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company * KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA * Acquisition strengthens ...

2025-09-08 15:49 837

Gushengtang's H1 2025 Net Profit Climbs 41.6% Driven by Digital Health Adoption and International Expansion

GUANGZHOU, China, Sept. 8, 2025 /PRNewswire/ -- On August 29, Gushengtang (HKG:2273) announced its interim results for 2025, reporting strong operational and financial performance. The company posted revenue ofRMB 1.49 billion, representing a 9.5% year-on-year increase. Net profit grew 41.6% year...

2025-09-08 15:35 5073

Siriraj × MIT Hacking Medicine 2025 Now Open for Applications Across Southeast Asia: A Call for Innovation to Tackle Greatest Healthcare Challenges

BANGKOK, Sept. 8, 2025 /PRNewswire/ -- Siriraj Hospital and MIT Hacking Medicine have joined forces once again to host the second edition of their medical innovation hackathon, Siriraj × MIT Hacking Medicine 2025, taking place fromOctober 31 to November 2, 2025. Applications are now open for part...

2025-09-08 14:39 2156

Sirnaomics Announces Strategic Equity Investment by Bloomage Biotech to Jointly Advance Next-Generation Life Science Pipelines

HONG KONG, Sept. 7, 2025 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; Stock Code: 2257), a leading biopharmaceutical company in discovery and development of advanced RNAi therapeutics, today announced that it has entered into a stra...

2025-09-08 12:15 1116

Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines

SHANGHAI, Sept. 7, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a$60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture Pa...

2025-09-08 10:00 1256

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

* The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 * In the North American patients, the OS HR was 0.70 * The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) ...

2025-09-07 18:08 1727

Huadong Medicine Announces Positive Preliminary Results from a Phase Ⅰ study of HDM2005, a ROR1-Targeting ADC

HANGZHOU, China, Sept. 5, 2025 /PRNewswire/ -- Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") today announced positive preliminary results from a Phase I study of HDM2005, an independently developed Class 1 innovative antibody–drug conjugate (ADC) targeting receptor ty...

2025-09-05 21:38 2602

'CART BP pro' Opens a New Paradigm in Blood Pressure Management, Maintaining Accuracy Across Arm Positions

SEOUL, South Korea, Sept. 5, 2025 /PRNewswire/ -- At the European Society of Cardiology (ESC) Congress 2025, held inMadrid from August 29 to September 1, Sky Labs presented new clinical findings on CART BP pro, its cuffless, ring-type blood pressure monitor. The device demonstrated consistent acc...

2025-09-05 20:48 1871

FUTUONING Sets Sail Commercially with First Prescriptions Across China

SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- These days, the first prescriptions of FUTUONING (fovinaciclib citrate capsules) were issued by more than ten hospitals acrossChina, including Fudan University Shanghai Cancer Center, Cancer Hospital of the Chinese Academy of Medical Sciences, The First Af...

2025-09-05 18:12 1843

Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

TAIPEI and SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted IND clearance for its innovative drug candidate Pidnarulex(CX-5461) ina Phase1b/2 clin...

2025-09-05 16:46 1389

Immunofoco Earns Spot on Forbes Asia 100 to Watch 2025 List for Leading New Wave in Solid Tumor Cell Therapy

SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Immunofoco, a clinical-stage biotechnology company, focused on developing novel cell therapies for solid tumors, has been selected for the prestigious "Forbes Asia 100 to Watch 2025" list. This annual list, compiled by the editors of Forbes Asia, spotlights...

2025-09-05 16:09 1630

Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use Urology Products

WESTBOROUGH, Mass., Sept. 4, 2025 /PRNewswire/ -- Olympus Corp., a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today an exclusive global distribution agreement with MacroLux Medical Technology Co., Ltd. to distribute single-...

2025-09-04 22:12 1509

Alma, a Sisram Medical Company, Announces Strategic Collaboration with Celebrity Skin Expert Nurse Jamie to Expand Global Consumer Presence

HONG KONG, Sept. 4, 2025 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions, today announced a strategic collaboration between its subsidiary Alma, a global leader in energy-based medical and aesthetic solutions, andJamie Sher...

2025-09-04 22:00 1651

Halia Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

LEHI, Utah, Sept. 4, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced that the Company plans to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. Jared Bearss...

2025-09-04 20:00 1398
1 ... 40414243444546 ... 644

Week's Top Stories